| Name | Title | Contact Details |
|---|
Aura Medsystems is a Duxbury, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Designated “Best of Nursing Homes 2019-2020 - Highest Performing Short-Term Stay” by U.S. News and World Report (Bloomingdale, Chicago Ridge, Elmhurst, La Grange, Lake Zurich, Lombard, Schaumburg) Designated “Best of Nursing Homes 2020” by Newsweek (Bloomingdale) Winner of McKnight`s Long-Term Care News Excellence in Technology "2017 Gold Innovator of the Year" for Curatess Telemedicine Platform Awarded "Best"/Top Performer by U.S. News and World Report: Lexington Health Care Center of Elmhurst Lexington Health Network is Chicagoland`s premier provider of post-acute care & rehabilitation, long-term care, memory care, independent & assisted living, home health care, hospice care and private duty nursing. As the leader of integrated health services, Lexington Health Network is with you, from hospital to home and beyond. Today, Lexington Health Network manages more than 2,000 skilled nursing beds in 10 different post hospital, nursing and long term care buildings as well as more than 500 independent retirement units and more than 150 assisted living units within 3 senior living centers. Our diverse network of health care services also offers home health care, hospice care and private care services. Lexington proudly employs more than 2,500 full and part time individuals enabling us to provide an immeasurable value to the communities we serve. So much of who we are comes from an integrated organization dedicated to the highest attainable quality of care available today. As a family-owned organization, we have always maintained a unique perspective. Whether you are a post-acute patient, resident, a family member, or an employee, you are considered an extension of our family. In an industry filled with rapid change and growth, the Lexington constant, of our commitment to family values, will never change. Welcome to the Lexington Health Network.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.
InSound Medical, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Cannus Partners Inc. operates as a specialty pharmaceutical company. The Company cultivates, processes, and distributes cannabis. Cannus Partners serves customers in the United States and Canada.